论文部分内容阅读
目的观察克拉霉素联合莫西沙星治疗耐多药肺结核的疗效。方法将耐多药肺结核患者88例按照就诊顺序随机分为试验组40例和对照组48例,试验组给予克拉霉素联合莫西沙星+常规化疗,对照组给予莫西沙星+常规化疗,比较2组临床疗效及1个月、3个月、6个月的痰转阴率。结果试验组治疗总有效率为95.0%高于对照组的89.6%,但差异无统计学意义(χ~2=0.87,P>0.05)。试验组治疗1个月后痰转阴率高于对照组,差异有统计学意义(P<0.05)。结论对耐药性结核患者予以常规化疗联合克拉霉素联合莫西沙星用药方案疗效确切,可提升其痰菌转阴率,值得临床推广。
Objective To observe the efficacy of clarithromycin combined with moxifloxacin in the treatment of multidrug-resistant pulmonary tuberculosis. Methods 88 cases of MDR-TB patients were randomly divided into experimental group (40 cases) and control group (48 cases), clarithromycin combined with moxifloxacin plus conventional chemotherapy in the experimental group, moxifloxacin plus conventional chemotherapy in the control group The clinical curative effect of group 2 and sputum negative rate of 1 month, 3 months and 6 months. Results The total effective rate of the experimental group was 95.0% higher than 89.6% of the control group, but the difference was not statistically significant (χ ~ 2 = 0.87, P> 0.05). The sputum negative conversion rate of experimental group after one month of treatment was higher than that of control group, the difference was statistically significant (P <0.05). Conclusions The conventional chemotherapy combined with clarithromycin and moxifloxacin regimen in patients with drug-resistant tuberculosis has definite curative effect, which can improve the rate of sputum negative conversion and deserve clinical promotion.